TILOS THERAPEUTICS
Tilos Therapeutics is developing antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company's initial work is on antibodies specific for Latency Associated Peptide of TGF beta. Tilos was founded in 2016 and is based in Cambridge, Massachusetts.
TILOS THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.tilostherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
508-233-3923
Email Addresses:
[email protected]
Total Funding:
3.8 M USD
Technology used in webpage:
Domain Not Resolving
Founder
Official Site Inspections
http://www.tilostherapeutics.com
Unable to get host informations!!!
More informations about "Tilos Therapeutics"
Tilos Therapeutics - Crunchbase Company Profile & Funding
Tilos Therapeutics is developing antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company's initial …See details»
Merck to Acquire Tilos Therapeutics - Merck.com
Jun 10, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a …See details»
Tilos Therapeutics Company Profile 2024: Valuation, Investors ...
Tilos Therapeutics General Information Description. Developer of antibody therapeutics designed to treat cancer, fibrosis and related disorders. The company's antibody therapeutics harnesses …See details»
Tilos Therapeutics Inc - Company Profile and News
Tilos Therapeutics, Inc. operates as a biotechnology company. The Company offers antibodies for the treatment of cancer, fibrosis, and autoimmune diseases. Tilos Therapeutics serves …See details»
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech - PubMed
Jun 28, 2021 Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of …See details»
Merck inks $773M Tilos takeout to bag TGFβ cancer programs
Jun 10, 2019 Merck has struck a $773 million detail to buy Tilos Therapeutics. The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the …See details»
Merck bolts on another immunology firm with $773m Tilos deal
Oct 19, 2024 Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its third pipeline-boosting deal in a little over four months. The deal gives …See details»
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech
Aug 1, 2019 Merck is joining the list of drug companies aiming to block TGFβ signaling to augment the tumor-killing potential of checkpoint inhibitors. The company announced in June …See details»
Merck to Acquire Tilos Therapeutics - Business Wire
Jun 10, 2019 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive …See details»
Merck expands in oncology with Tilos buy | C&EN Global Enterprise
Jun 17, 2019 Merck & Co. is expanding its immunotherapy portfolio with the purchase of Tilos Therapeutics. The deal, worth up to $773 million, gives Merck a stable of cancer therapies …See details»
Merck set to acquire Tilos Therapeutics for $773 million
Jun 12, 2019 By Rajaneesh K. Gopinath, Ph.D. This is Merck’s third oncology company acquisition this year, after Immune Design and Peloton Therapeutics. O n June 10 th, Merck & …See details»
Merck Buys Tilos for Up to $773 Million to Expand Oncology Pipeline
Jun 10, 2019 Kenilworth, NJ-based Merck & Co. is buying Lexington, Mass.-based Tilos Therapeutics in a deal that could hit $773 million. Tilos focuses on developing drugs that target …See details»
Merck & Co. Expands Pipeline in Cancer, Fibrosis, Autoimmune …
Jun 11, 2019 Merck & Co. plans to acquire Tilos Therapeutics for up to $773 million, in a deal designed to expand the buyer’s cancer, fibrosis, and autoimmune disease pipelines with …See details»
Merck acquires Tilos for $773m - biopharma-reporter.com
Jun 11, 2019 Following the agreement, Merck, known as MSD outside of the US and Canada, will acquire all of Tilos Therapeutics’ shares for up to $773m (€683m), through an unspecified …See details»
After $700M-plus Merck buyout, Tilos CEO Fox lands at Rheos …
Oct 21, 2019 Barbara Fox, Ph.D., is getting right back on the horse. | Barbara Fox, Ph.D., is getting right back on the horse. Fresh off Tilos Therapeutics’ $773 million sale to Merck, Fox is …See details»
Merck to acquire Tilos Therapeutics for $773m - Pharmaceutical …
Merck has signed an agreement to buy biopharmaceutical company Tilos Therapeutics for a total consideration of up to $773m. Founded by Boehringer Ingelheim Venture Fund and Partners …See details»
Merck in $773m deal to add preclinical MAb firm Tilos
Jun 11, 2019 The deal will see biopharma firm Merck acquire private Massachusetts-based biotech Tilos Therapeutics for up to $773 million (€683 million), including an undisclosed …See details»
Tilos Therapeutics to Be Acquired by Merck - Wilson Sonsini …
On June 10, 2019, Merck, a leading global biopharmaceutical company, announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held …See details»
Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m …
Merck has signed an agreement to acquire biopharmaceutical firm Tilos Therapeutics in a deal valued at around $773m (£608m). Image: Merck has agreed to acquire biopharmaceutical firm …See details»
Merck to buy private Tilos in deal worth up to $773M
Jun 10, 2019 Dive Brief: Merck & Co. said Monday it will buy Tilos Therapeutics, a drug developer focused on targeting a powerful cytokine called TGF-beta as a way to treat cancer, …See details»